Benzinga
09 Feb 2026, 18:03 UTC · 31w ago
Verdict
Headline takes no side. We score HIMS −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Hims & Hers announced it will stop offering its compounded oral semaglutide pill following regulatory pressure.
More negative than 99% of claims this week
Novo Nordisk has filed a major patent infringement lawsuit against Hims & Hers.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 95% of claims this week
Hims & Hers shares fell over 20% to new 52-week lows on high trading volume.
More negative than 80% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
Shares crashed to 52-week lows following a federal crackdown on its oral semaglutide pill and a patent infringement lawsuit.
More positive than 76% of ticker scores this week
The company is aggressively protecting its intellectual property by filing a major patent infringement lawsuit against a competitor.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Globe News Wire
1h ago
MarketBeat
2h ago
+25.2%
Price is moving against the score
$28.81 vs $23.02 close before publication (Feb 6) · not market-adjusted
HIMS chart →
